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TESTOSTERONE REPLACEMENT THERAPY 
 
MICHAEL ANDREW VROLYK 
ABSTRACT 
 Physicians and scientists have suspected that the testes secrete a substance into the 
body that causes male secondary sexual characteristics for hundreds of years. However, 
testosterone was not synthesized until 1935 and it was not until the 1940’s when 
scientists could accurately measure the amount of this hormone in the blood. Since then, 
scientists have been able to make correlations between the levels of testosterone in the 
body and men’s health  
 Scientists have long observed higher levels of testosterone to be associated with 
an increase in levels of Hematocrit (Hct). As a result, Testosterone Replacement Therapy 
(TRT) has been used to treat anemia associated with chronic diseases. In recent years, 
prescription sales for testosterone have sky rocketed due to new clinical uses such as 
androgen deficiency in older men. In fact, the rate of prescription for testosterone 
products has increased by over 170% in the previous five years. 
 Long-term data shows that the level of testosterone in the male body begins to 
decrease at about the age of 30. As the life expectancy of the general population 
continues to increase, TRT may be a viable option for older men with low testosterone to 
increase the quality and duration of life. However, an increase in Hct continues to be a 
major side effect of TRT. New research is beginning to make clear the mechanism by 
which testosterone affects erythropoeisis. 
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 New research suggests TRT suppresses hepcidin and leads to an increase in the 
rate of iron (Fe) retention in red blood cells (RBCs). Inter-individual differences in the 
pharmacogenetic effects of TRT have been observed. In the future TRT could be 
genetically tailored based on the individuals DNA. In this case, the optimal dose of 
testosterone can be given to maximize benefits and reduce side effects. 
 Here, the risks and benefits associated with TRT and a review of the updated 
Clinical Guidelines for its use will be presented. The effects of TRT on erythropoeisis 
will be investigated via a review of the literature. The main objective of this review is to 
provide a general understanding of TRT and a major side effect of its use, excessive 
erythropoeisis.  
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INTRODUCTION 
 
Early History 
 The primary source of testosterone and its phenotypic effects have been known 
for about 6,000 years when Neolithic farmers discovered castration of animals improved 
their domestication (Freeman et al., 2001). Figure 1 is a depiction of Neolithic farmers 
with domesticated animals. However, the genotypic effects of testosterone on the human 
body have still not been fully elucidated at present.  
 
 
Figure 1. Depiction of Neolithic Farmers with Domesticated Animals 
“Neolithic Settlement” Zdenek Burian, 1948 
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 The modern era of testosterone began in 1849 when Arnold Berthold investigated 
the effects of castration and transplantation on roosters. Berthold found that when 
roosters were castrated at a young age they suffered from a lack of physical and 
behavioral development typical of normal roosters (Soma, 2006). When Berthold 
transplanted testes back into young castrated roosters, normal development was observed 
(Figure 2). Furthermore, Berthold discovered new vascular connections in the 
transplanted testes. Berthold concluded that the testes are generating something that 
affects behavioral and sexual characteristics (Soma, 2006). 
 
 
Figure 2. Effects of Castration on Male Chick 
An Introduction to Behavioral Endocrinology 4th Edition, Nelson 2011 
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Evolution of Endocrinology 
 The fountain of youth has been an age-old dream of humankind. People have long 
used extreme measures to prevent or reverse normal aging and senescence (Kozminski et 
al., 2011). In 1889 Charles Edouard Brown-Sequard (Figure 3) reported “he had 
increased his physical strength, mental abilities and appetite by self-injection with an 
extract derived from the testicles of dogs and guinea pigs” (Freeman et al., 2001). Brown-
Sequard argued that “spermatic anemia” resulted in fatigue and senility that could be 
treated by increasing the level of sperm or testicular substance in the blood stream 
(Kozminski et al., 2011). This claim led to the development of “Organotherapy”, a field 
of research dedicated to the treatment of diseases with extracts from animal organs 
(Freeman et al., 2001). 
 
 
Figure 3. Charles Edouard Brown-Sequard 
Figures and Institutions of the Neurology Sciences in Paris from 1800 to 1950. Part 
II: Neurophysiology. Barbara et al., 2012 
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 By the end of 1889, manufacturing chemists were making fortunes selling extracts 
from animal testes, which claimed to be the “Elixir of Life” (Figure 4), even though 
Brown-Sequard’s claims were never scientifically proven. In addition, the risks 
associated with the use of animal extracts to treat diseases were never publicized. As a 
result, many patients were at serious risk of infection and inflammation from its use. 
Nevertheless, the new medical field of organotherapy continued to advance rapidly 
(Freeman et al., 2001). 
 
 
Figure 4. The “Elixir of Life” 
Dunbar et al., 1889 
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 In 1902 William Bayliss and Ernest Starling (Figure 5) recovered an interesting 
extract from the lining of the small intestine they called “secretin” because it activated the 
secretion of water and bicarbonate by the pancreas (Freeman et al., 2001). This discovery 
supported the theory of organotherapy and eventually led to the development of modern 
day endocrinology. The discovery of secretin suggested that the secretion of substances 
from one organ can be responsible for physiological occurrences seen in another organ 
(Freeman et al., 2001). 
 
 
Figure 5. William Bayliss (bottom right) and Ernest Starling (top left) 
Ernest Starling and the Discovery of Secretin. Modlin et al., 2001 
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 Bayliss and Starling continued to ambiguously refer to these blood borne 
messengers as “chemical messengers” until William B. Hardy proposed the name 
hormone in 1905. Hardy derived the term hormone from the Greek word horman 
meaning “I arouse to activity,” as in “setting something in motion.” Bayliss and Starling 
postulated that hormones have receptors far from the site of origin that influence many 
functions in the body (Freeman et al., 2001). 
 
The “Steinach Operation” 
 Work in the late 19th century suggested that fatigue and senility, particularly in 
men, could be treated with a substance found within the testicle. Accordingly surgeons 
implemented techniques to enhance or supplement rejuvenating material in men 
(Kozminski et al., 2011). The famous “Steinach Operation” was invented in 1920 by the 
Viennese physiologist Dr. Eugene Steinach (Figure 6). The “Steinach Operation” 
consisted of unilateral vasoligation of the vas deferens; essentially the operation was a 
vasectomy. Figure 7 shows the same person before and after the “Steinach Operation.” 
“Steinach argued that the sex gland contained puberty cells and reproductive cells. 
Steinach believed that disrupting the outflow tract of the sperm producing cells would 
lead to a back pressure, resulting in atrophy of this portion of the testis. As the one 
portion atrophied, the other had to proliferate to prevent a vacuum within the body” 
(Kozminski et al., 2011). This treatment for middle-aged listless males became a popular 
procedure until the discovery of testosterone (Freeman et al., 2001). 
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Figure 6. Dr. Eugen Steinach 
Figure adopted from ‘Dr. Steinach Coming to Make Old Young!’: Sex Glands, 
Vasectomy and the Quest for Rejuvenation in the Roaring Twenties (Sengoopta, 
2003) 
 
 
Figure 7. Before (left) and After (right) the “Steinach Operation”  
Kahn, 2007 
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 William Butler Yeats was an Irish poet and Nobel Prize winner who underwent 
the “Steinach Operation” at the age of 69. In 1937, referring to the “Steinach Operation” 
Yeats wrote, “It revived my creative power. It revived also sexual desire; and that in all 
likelihood will last me until I die.” Sigmund Freud and numerous others underwent the 
procedure in the “belief that it would rejuvenate them physically, mentally and sexually” 
(Freeman et al., 2001). 
 
The Discovery of Testosterone 
 By the 1930’s chemists were still attempting to capitalize on the popularity of 
organotherapy brought about by Brown-Sequard nearly half a century earlier. In 1935, 
the publication of “On Crystalline Male Hormone from Testicles (Testosterone),” 
identified a new hormone produced by the testes (PubChem; Figure 8). Testosterone 
proved to be a powerful androgenic factor, responsible for male secondary 
characteristics.  
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Figure 8. Chemical Structure of Testosterone 
Figure adopted from PubChem - testosterone 
 
 In 1935, just one week before Ruzicka et al published “On the Artificial 
Preparation of the Testicular Hormone Testosterone (Andro-sten-3-one-17-ol),” 
Butenandt et al published “A Method for Preparing Testosterone from Cholesterol 
(Freeman et al., 2001).” Ruzicka et al and Butenandt et al were both offered the 1939 
Nobel Prize in chemistry however; Butenandt was forced to decline the Nobel Prize by 
the Nazi government (Freeman et al., 2001). 
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Figure 9: Pathway for Testosterone Synthesis 
Erogenic Aids: Counseling the Athlete, Ahrendt, 2001 
 
Recent History  
 After the discovery of testosterone, the effects of this hormone on the human body 
could be scientifically evaluated by measuring the amount of testosterone in the blood. 
Men’s elevated concentration of Hemoglobin (Hb) and Hct as compared to women’s has 
been attributed to men’s elevated levels of testosterone. Due to testosterone’s effect on 
Hb and Hct, it was the main pharmacologic agent used to treat patients suffering from 
anemia before recombinant hematopoietic growth factors became available (Rochira et 
al., 2008). 
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 Recently the influence of testosterone on physical well-being has become a focus 
of research attention. Particularly, the risk benefit ratio of TRT in treating a variety of 
conditions has been studied. Demographic data indicates that the population in older age 
groups is increasing. Low testosterone in older men has become an interesting topic of 
discussion. Studies routinely indicate that testosterone levels decrease with age and that 
many men over the age of 60 years have testosterone levels below the lower limit of 
normal for men aged 20-30 years. The main question raised is whether older men with 
low levels of testosterone will benefit from TRT (Wang et al., 2008.) 
 
Effects of TRT on Erythropoeisis 
 TRT is associated with increases in the rate of erythropoeisis and therefore an 
increase in Hct (Fernandez-Balsells, 2010). However, the mechanism by which TRT 
increases the rate of erythropoeisis remains poorly understood (Bachmen et al., 2010). 
Understanding the underlying mechanism by which TRT stimulates erythropoeisis may 
help to prevent an excessive increase in Hct during TRT (Guo et al., 2013). The clinical 
significance of these findings and the effects on patient-important outcomes such as 
mortality and cardiovascular events requires further investigation (Fernandez-Balsells, 
2010). Clarification of factors that modify the effect of testosterone on erythropoeisis 
would better inform the medical field and the general public about the risks and benefits 
of TRT and thereby improve medication safety (Spitzer, 2013).  
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Aims 
 Therefore, the primary objective here is to present the risks and benefits 
associated with TRT. A review of the updated Clinical Guidelines will be presented and 
the effects of TRT on erythropoeisis will be investigated via a review of the literature. 
Lastly, a suggestion for the future of TRT will be proposed. We hope this will bring 
about a more general understanding of the risks and benefits of TRT in the clinical 
setting. 
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PUBLISHED STUDIES  
Risks versus Benefits of Testosterone Therapy in Elderly Men. Basaria et al 
1999.  
Physiology of Testosterone 
 Testosterone secretion begins in utero, during an early “sensitive period”, that can 
be seen as a peak in testosterone concentration in the male fetus at about 12 weeks. A 
second peak is observed after birth. From birth up until puberty, Luteinizing Hormone 
(LH) is secreted in a pulsatile fashion leading to the maturity of the Leydig cells. The 
maturation of the Leydig cells leads to increased levels of testosterone in the body 
(Basaria et al., 1999). Testosterone is required for the healthy development, maintenance, 
and physiological functions of many organs in males throughout life (Ullah et al., 2014).  
 Testosterone secretion is controlled by a negative feedback mechanism; a 
decrease in the concentration of testosterone in the blood stream will cause the 
hypothalamus to release Gonadotrophic Releasing Hormone (GnRH). The increase in 
GnRH will then signal the pituitary to release LH and Follicle-Stimulating Hormone 
(FSH).  LH and FSH signal the Leydig cells of the testes to secrete testosterone into the 
blood stream (Figure 10). Conversely, a high concentration of testosterone in the blood 
stream will cause a decrease in the rate of production. Testosterone signals both the 
hypothalamus and the pituitary to stop releasing GnRH, LH, and FSH (Basaria et al., 
1999).  
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Figure 10. Hypothalamic-Pituitary-Gonadal Axis and Testosterone Secretion 
Figure adapted from Ullah et al., 2014 
 
 The average adult male produces 0.24 micromoles of testosterone daily. Only 2% 
of testosterone is in the blood as free testosterone; 18% has a weak bound with albumin, 
while 80% has a strong bound with Sex Hormone-Binding Globulin (SHGB) (Nigro et 
al., 2012; Basaria et al., 1999). The testosterone that is bound to SHBG is not considered 
usable by most target organs because it is bound too tightly. Therefore only about 20% of 
the testosterone concentration is considered usable by the body (Surampudi et al., 2012). 
Studies have shown the aging male can suffer from a 1-2% decrease of total testosterone 
levels per year, beginning at about the age of 30. A concomitant increase in SHBG with 
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aging has also been observed, such that the decline in free testosterone is even more 
significant in older males (Nigro et al., 2012).  
 
Risks Associated with Low T 
 Low testosterone concentrations in older males are associated with declining 
physical and cognitive performance, increased cardiovascular morbidity, and all-cause 
mortality (Figure 11). Older men have an increased risk of anemia (Yeap et al., 2009). 
Anemia “is associated with an increased risk of falls and fractures, cognitive impairment, 
mortality, and decreased physical ability. Anemic men older than 85 years had more than 
twice the risk of death than men without anemia” (Paller et al., 2012). 
 
 
Fig 11: Low T is Associated with Shorter Survival 
Men with low and equivocal T levels had shorter survival than men with normal T 
levels. Low T = total T < 250 ng/dL or free T < .75 ng/dL 
Figure adapted from Traish et al., 2010 
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Benefits of TRT 
 TRT has been shown to restore testosterone levels to within the normal range for 
young men. TRT has also been shown to improve mood, energy levels and patients’ 
sense of well-being. Studies also show improvements in sexual function, lean body mass 
and muscle strength (Gooren, 2010). Recent studies show short-term beneficial effects of 
TRT in elderly men on multiple target organs however there is little long-term data. The 
effects of TRT on functional benefits that may delay physical or mental frailty of older 
males or improve the quality of life of the elderly are also very limited.  
 
Risks of TRT  
 There is a correlation in men between the amount of testosterone in the plasma 
and the level of Hb. Higher levels of testosterone are associated with higher levels of Hb. 
A recent study demonstrated a TRT dose-dependent stimulatory effect on erythropoeisis 
(Synder et al., 2000) (Figure 12). Higher values of Hb and Hct are associated with 
vascular conditions such as cerebral vascular accidents and coronary heart disease 
(Gooren, 2010). The Honolulu Heart Program and The Framingham Heart Study both 
found a high Hct to be a risk factor of death from cardiovascular disease (Paller et al., 
2012). However, due to a lack of large-scale long-term data, a relation between increases 
in Hct as a result of TRT and the risk for any cardiovascular event in general has not been 
demonstrated (Gooren, 2010).  
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Figure 12. Mean (+/- SE) serum testosterone, Hct, and Hb values in men with 
previously untreated hypogonadism who were treated with TRT for 36 months 
(Synder et al., 2000). 
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Conclusion 
 Due to the growing interest from practitioners on TRT as a treatment for low 
levels of testosterone in adult men, the Clinical Guidelines Subcommittee of The 
Endocrine Society selected a Task Force to update the guidelines for the evaluation and 
treatment of low testosterone levels in men (Wang et al., 2008). 
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Testosterone Therapy in Men with Androgen Deficiency Syndromes: An 
Endocrine Society Clinical Practice Guideline. Bhasin et al., 2010.  
Hypogonadism 
 Hypogonadism is defined as a clinical syndrome resulting from the failure of the 
testis to produce normal levels of testosterone and a normal number of spermatozoa due 
to a malfunction in the hypothalamic-pituitary-testicular axis (Bhasin et al., 2010).  
 Malfunctions in the hypothalamic-pituitary-testicular axis can be described as 
primary or secondary testicular failure. Malfunctions at the testicular level cause primary 
testicular failure, while abnormalities in the hypothalamus or pituitary cause secondary 
testicular failure. Hypogonadism can also reflect defects of both primary and secondary 
testicular failure (Bhasin et al., 2010). 
 “Primary testicular failure results in low testosterone levels, impairment of 
spermatogenesis, and elevated GnRH levels. Secondary testicular failure results in low 
testosterone levels, impairment of spermatogenesis, and low or low-normal GnRH levels. 
Combined primary and secondary testicular failure results in low testosterone levels, 
impairment of spermatogenesis, and variable GnRH levels, depending on whether 
primary or secondary testicular failure predominates” (Bhasin et al., 2010). 
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Late-Onset Hypogonadism  
 Late-Onset Hypogonadism (LOH) is defined as a clinical and biochemical 
syndrome characterized by symptoms associated with older age and testosterone levels 
below the reference range fore young healthy adult men (Wang et al., 2008). It is 
believed LOH is primarily due to testicular dysfunction based on the observed decrease 
number and volume of Leydig cells, impaired testicular perfusion, and impaired steroid 
biosynthesis in aging men (Basaria et al., 1999) however, an additional hypothalamic 
component is also possible (Nigro et al., 2012). It is believed LOH may result in a 
decrease in the quality of life and adversely affect the function of several organ systems 
(Wang et al., 2008). 
 
Clinical Guidelines 
 The Clinical Guidelines Subcommittee of The Endocrine Society updated the 
guidelines for the evaluation and treatment of androgen deficiency syndromes in adult 
men in 2010. The Task Force suggests only making a diagnosis of hypogonadism in men 
with signs and symptoms suggestive of low testosterone (Table 1) and consistently low 
serum testosterone levels (Bhasin et al., 2010). 
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Table 1. Signs and Symptoms Suggestive of LOH in Men (Bahsin et al., 2010). 
More Specific Signs and 
Symptoms 
Less Specific Signs and 
Symptoms  
Incomplete or delayed 
sexual development, 
eunuchoidism 
Decreased energy, 
motivation, initiative, and 
self-confidence 
Reduced sexual desire 
(libido) and activity  
Feeling sad or blue, 
depressed mood, 
dysthymia 
Decreased spontaneous 
erections 
Poor concentration and 
memory  
Breast Discomfort 
gynecomastia 
Sleep Disturbance, 
increased sleepiness 
Loss of body (axillary and 
pubic) hair, reduced shaving 
Mild anemia 
Very small (especially 
<5ml) or shrinking testes 
Reduced muscle bulk  
Height loss Increased body fat 
 
 
 The Task Force suggests taking a blood sample in the morning to determine the 
patients’ total testosterone level. The initial testosterone level should be confirmed by 
repeating a morning blood sample at least one more time. The Task Force notes that some 
men may have total testosterone levels that are near the lower limit of normal and still be 
experiencing symptoms of LOH. In these men, blood samples should be taken to 
determine the amount of serum SHBG. High levels of SHBG would bind a larger 
percentage of testosterone therefore decreasing the amount of free testosterone available 
in the patient. Figure 13 depicts an approach for the diagnostic evaluation of adult men 
with signs and symptoms suggestive of LOH. They recommend TRT for men with 
symptomatic androgen deficiency to induce and maintain secondary sex characteristics 
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and to improve their sexual function, sense of well-being, muscle mass and strength, and 
bone mineral density (Bhasin et al., 2010).  
 
 
Figure 13. An Approach for the Diagnostic Evaluation of Adult Men Suspected of 
Having Androgen Deficiency (Bahsin et al., 2010). 
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 The Task Force recommends evaluating patients at baseline, 3 months, and 6 
months after beginning TRT and then yearly to evaluate the pateints’ symptoms and 
determine in the patient is suffering any side effects. Blood samples should be drawn at 
each visit, with the goal of reaching serum testosterone levels in the mid-normal range for 
young adult men (Bahsin et al., 2010). 
 The Task Force found TRT to cause a dose-dependant increase in Hct due to 
excessive erythrocytosis as one of the most common side effects. “Testosterone treated 
men were nearly four times more likely than placebo-treated men to experience Hct 
above 50%”(Bahsin et al., 2010). The Task Force notes more research is needed to 
elucidate how testosterone effects erythropoeisis and causes an increase in Hct . 
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Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for 
Testosterone-Induced Erythrocytosis. Bachmen et al., 2010. 
Hepcidin 
 Hepcidin regulates the amount of iron (Fe) available for RBC production by 
competing for Fe absorption sites in the small intestine. Hepcidin binds to the Fe 
transport protein, therefore preventing Fe from binding and being transported into the 
body for RBC production (Guo et al., 2013). 
 Bachmen et al hypothesized that testosterone increases Hct by decreasing the 
concentration of hepcidin. Hepcidin is a liver-derived peptide responsible for regulating 
the availability of Fe within the body. Increased levels of hepcidin correlate with a 
decrease in systemic Fe bioavailablity and result in mild anemia. Conversely, decreased 
levels of hepcidin increase iron bioavailability and therefore lead to an increase in RBC 
production (Bachmen et al., 2010). 
 To test their hypothesis, men were stratified based on age and varying doses of 
TRT for 20 weeks. In order to generate stable levels of testosterone, all subjects received 
monthly injections of GnRH agonist to suppress endogenous testosterone production 
(Bachmen et al., 2010). Subjects received weekly doses of 25, 50, 125, 300, or 600 mg 
TRT to produce the 5 cohorts of subjects within each age group (Figure 14 and 15) 
(Bachmen et al., 2010). Finally, testosterone, free testosterone, Hct, Hb, serum 
erythropoietin, ferritin, serum iron, iron binding capacity, and percentage saturation were 
measured at week 0, 1, 2, 4, 8, and 20 (Bachmen et al., 2010). 
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Figure 14. Testosterone Dose-Dependently Suppresses Serum Hepcidin (Bachman et 
al., 2010). 
 
TRT Effects on Hepcidin  
 Testosterone increased Hct and Hb dose-dependently. High testosterone levels 
results in a 60% suppression of serum hepcidin levels within one week and all dose 
groups experienced at least a 50 % decline in hepcidin. Serum hepcidin levels were 
suppressed in the higher testosterone dose groups in younger men and dose-dependently 
suppressed in older men. Graded increases in serum testosterone were associated with 
graded suppression of serum hepcidin to a maximum of 60% in the 300 and 600 mg/week 
groups. Testosterone dose was highly correlated with suppression of hepcidin and this 
effect remained highly significant throughout the treatment duration. They estimate a 100 
ng/dl increase in serum testosterone level was associated with a 14.9% decrease in serum 
hepcidin (Bachmen et al., 2010).  
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Figure 15. Effects of Testosterone on Hepcidin (Bachman et al., 2010) 
 
Conclusion 
 Older men had higher baseline hepcidin levels and experienced significantly 
greater suppression of hepcidin levels for any dose of testosterone compared to younger 
men. Hepcidin levels at week four were inversely correlated with Hct levels at week 16 
however; a greater level of significance was seen in older men. Therefore, men with the 
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greatest change in hepcidin levels also had the greatest risk of developing erythrocytosis 
during TRT (Bachmen et al., 2010).  
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Testosterone Administration Inhibits Hepcidin Transcription and is 
Associated with Increased Iron Incorporation into Red Blood Cells. Guo et 
al., 2013 
TRT Effects on Hepcidin 
 Guo et al show that testosterone regulates the amount of hepcidin and causes an 
increase in Fe availability for RBC production. Gue et al were also able to demonstrate 
how testosterone influences hepcidin availability. It was shown that testosterone activates 
the Androgen Receptor (AR) and interferes with bone morphogenetic protein 
(BMP)/Smad signaling to reduce hepcidin transcription (Guo et al., 2013). 
 Adult mice were administered testosterone via subcutaneous implants. After a lag 
of two days, a gradual increase in Hct was observed. Significantly higher levels of Hb 
and Hct were seen two weeks post testosterone administration as compared to mice in the 
control group. Serum Fe, transferrin saturation, reticulocyte count, and reticulocyte Hb 
ratio were also significantly higher in the testosterone group than placebo group (Guo et 
al., 2013). However, total Fe binding capacity was significantly lower in the testosterone 
group. Therefore, it was evident that TRT stimulates erythropoeisis and increases 
markers of Fe bioavailability for erythropoeisis (Guo et al., 2013). 
  Testosterone administration was associated with nearly a 70% decrease in 
hepcidin availability (Guo et al., 2013). To further elucidate the effects of testosterone on 
hepcidin availability, mice with an over-expression of hepcidin gene (Tg+) and mice 
carrying a silent hepcidin gene (Tg-) were administered TRT. Hepcidin mRNA 
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expression was significantly higher in Tg+ than in Tg-. Therefore, Guo et al 2013 
postulated that if hepcidin suppression were essential for mediating testosterone’s effects 
on Hb, then TRT would not increase Hb in Tg+ mice. TRT did not cause any significant 
increases in Hb or Hct in Tg+ mice. However, TRT-treated Tg- female mice exhibited 
significant increases in Hb and Hct compared to baseline. These data indicate that 
regulation of hepcidin by TRT is important for mediating TRT-induced increases in Hb 
(Guo et al., 2013). 
 
RBC Fe 
 The Fe available for erythropoeisis is provided either from dietary intake or from 
the recycling of Fe in RBCs (Guo et al., 2013). The recycling of Fe from old RBCs 
provides the majority of Fe available for new RBC production over short durations. 
However, the absorption of Fe through dietary intake regulates the availability of Fe over 
long periods. The spleen produces proteins responsible for the recycling of RBC Fe. 
Ferroportin is one such protein produced by the spleen that recycles RBC Fe (Guo et al., 
2013).  
Guo et al demonstrated that the spleens of TRT-treated mice had significantly 
higher expression of ferroportin as compared to non-TRT-treated mice. Furthermore, 
TRT-treated mice had significantly lower Fe stores within the spleen. This result was 
expected, as ferroportin promotes Fe transport out of the spleen. Therefore, increased 
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ferroportin expression would increase the iron recycled by spleen back into blood and 
therefore reducing the amount of Fe in the spleen (Guo et al., 2013). 
 Guo et al used an intravenous injection of Fe tracers to determine the effects of 
TRT on Fe incorporation into RBCs. The previous findings of increased serum Fe, 
increased transferring saturation, and decreased splenic Fe retention were expected to 
favor Fe incorporation into RBCs for heme/Hb synthesis (Guo et al., 2013). Indeed, the 
amount of Fe available for RBCs was much larger in testosterone-treated mice than in the 
control group (Guo et al., 2013). 
 Erythroid cells incubated with either serum from testosterone-treated mice or 
serum from non-testosterone-treated mice were used to determine if increases in Fe 
availability in TRT-treated mice was associated with increased Hb synthesis (Guo et al., 
2013). Incubation with testosterone-treated mice was associated with significantly greater 
Hb accumulation than with serum from the control group (Guo et al., 2013). 
 
TRT and Hypoxia 
 It has been shown that TRT causes several physiological adaptations, for example 
increased Hb, Hct, EPO, and increased tissue capillarity that are similar to those induced 
by exposure to high altitude or hypoxia (Guo et al., 2013). Hypoxia-inducible factors 
have been shown to regulate transcription of hepcidin expression; therefore Guo et al 
determined whether down regulation of hepcidin by TRT is associated with the hypoxia-
sensing mechanism. RBC 2,3-BPG levels were higher in testosterone-treated mice, which 
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would be expected to shift the oxygen/Hb dissociation curve to favor oxygen 
dissociation. Guo et al. found testosterone did not induce hypoxia-sensing mechanisms in 
the liver and kidney; instead testosterone induced adaptations that increase tissue oxygen 
delivery i.e. increased Hb, Hct, and 2,3-BPG (Guo et al., 2013). 
 
TRT and The Androgen Receptor 
 BMPs and their downstream targets are important regulators of hepcidin 
transcription (Guo et al., 2013). In response to BMP activation, Smad1/5/8 translocates 
into the nucleus of the cell and binds to Smad4 (Guo et al., 2013). The Smad1/5/8-4 
complex then binds to other cofactors to form a transcription factor (Guo et al., 2013). 
The transcription factor then binds to BMP-responsive elements located in the hepcidin 
gene to generate transcription (Guo et al., 2013). Inhibitors of Smad1 have been shown to 
decrease hepcidin expression (Guo et al., 2013). 
 Guo et al found TRT to increase liver AR expression however, TRT increased 
rather than decreased Smad1 in the liver. With the increase in AR expression after 
testosterone injection, the association of AR with Smad1 and Smad4 was enhanced. Guo 
et al concluded that AR associates with Smad1 and Smad4 via direct binding, thereby 
impairing hepcidin transcription. Guo et al also proved that TRT reduced the protein-
DNA binding between Smad1 as well as Smad4, and the BMP/Smad-response elements 
in the hepcidin promoter. Therefore, TRT influenced the amount of hepcidin expression 
mostly at the level of gene transcription (Guo et al., 2013). 
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Pharmacogenetics of Testosterone Replacement Therapy. Zitzmann et al., 
2007. 
Introduction 
 TRT has been used for about 60 years with inter-individually different responses 
(Zitzmann, 2009). One hypothesis for the different responses seen in patients is the 
pharmacological effect of TRT on the AR gene. Pharmacogenetics is a new field of 
medicine dedicated to individual differences in genetic make-up and how that affects the 
response to medication. Zitzmann notes that the diagnosis of LOH has been constrained 
by strict definitions of thresholds for normal serum testosterone concentrations. New 
research into symptom specific thresholds for LOH and genetically determined degrees 
of testosterone action, are changing the concept of normal testosterone levels (Zitzmann, 
2009). In the future, individually tailored TRT may become available to optimize the risk 
benefit ratio of LOH men (Zitzmann, 2009). 
 The AR is located within the cell and it is structurally related to other steroid 
hormone receptors (Zitzmann, 2009). After entering the cell, testosterone interacts with 
the ligand-binding pocket of the AR and activates a cascade that ultimately results in 
either activation or repression of target gene transcription (Zitzmann, 2007) 
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Clinical Implications of Androgen Receptor Polymorphisms 
 The normal development of males is regulated by the interaction of testosterone 
with the AR in target tissues (Zitzmann, 2009). A range of clinical conditions has been 
correlated with mutations in the AR (Zitzmann, 2009). Differences in transcriptional 
activity caused by the AR have been attributed to a polyglutamine stretch in the AR 
receptor (Zitzmann, 2009). This polyglutamine stretch is encoded by a variable number 
of CAG triplets in exon 1 of the AR gene (Figure 16) (Zitzmann, 2009). The normal 
range of CAG repeats is between 9-37 (Zitzmann, 2007). 
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Figure 16. Display of The X-chromosome with the AR gene (Zitzmann, 2007) 
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 The modulatory effect on AR gene transcription appears to be linear and regulated 
by coactivator proteins of the polyglutamine stretch (Zitzmann, 2009). Men presenting 
with features of LOH may have normal testosterone levels but also have CAG repeat 
lengths above the normal range. A CAG repeat length longer than 25 is still considered to 
be within the normal range, however it is probably associated with a decrease in 
testosterone action (Zitzmann, 2009). This particular patient would have signs and 
symptoms suggestive of LOH but have testosterone levels within the normal range. 
Therefore, this patient would not be eligible for TRT based off of the Task Force’s 
recommendations for the evaluation and treatment of LOH with TRT.  
 
Pharmacogenetic Implications of the CAG Repeat Polymorphism 
 In 48 hypogonadal men with Klinefelter syndrome, baseline LH and Hb 
concentrations were not associated with CAG repeat length (Zitzmann, 2009). However 
after TRT, suppression of LH concentrations and elevation of Hb concentrations were 
more significant in men with shorter CAG repeats (Zitzmann, 2007). 
 
A Hypothetical Model of Androgen Action 
 Testosterone levels within the normal reference range will mostly saturate ARs. 
Studies have shown the androgenic effects of TRT reach a plateau at certain levels, most 
likely due to total AR saturation (Zitzmann, 2009). Significant increments in the effects 
of TRT caused by increasing testosterone concentrations are only seen beyond the normal 
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reference range (Zitzmann, 2009). It can be assumed that genetically determined 
functional differences in AR activity can be best observed within the normal range of 
testosterone (Zitzmann, 2009). However, in LOH androgenicity will be dependent on 
amount of testosterone available to bind with ARs (Zitzmann, 2007). 
 When examining the effects of testosterone, regression models are required to 
include both testosterone concentrations and the length of the AR CAG repeat 
polymorphism (Zitzmann, 2007). 
 During TRT of hypogonadal men, effects of testosterone will be induced by the 
increase in testosterone levels from the low into the normal range. TRT will also be 
mediated through the AR CAG repeat polymorphism (Zitzmann, 2009). The effect of the 
AR CAG repeat does not become a factor until normal testosterone levels have been 
reached (Zitzmann, 2007). 
 However, testosterone effects seem to follow a nonlinear pattern, when baseline 
total testosterone levels and AR CAG repeat length taken into account at the same time 
(Zitzmann et al., 2007). Zitzmann et al present a nonlinear model derived from general 
hormone kinetics to describe the effects of testosterone treatment on Hct (Figure 17). In 
agreement with previous studies, an AR CAG repeat length greater than 25 seems to 
require testosterone levels above the normal range (Zitzmann et al., 2007). Men with AR 
CAG repeat lengths larger than 25 may present with signs and symptoms suggestive of 
LOH but have normal testosterone levels (Zitzmann et al., 2007). According to the 
number of AR CAG repeats, the testosterone level may be individually tailored to 
achieve an optimal risk benefit ratio (Zitzmann, 2007). 
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Figure 17. Nonlinear Pharmacogenetic Model to Describe the Effects of T Levels 
and AR Polymorphism on Hct (Zitzmann, 2007) 
 
Conclusion 
 Zitzmann et al concluded that a general threshold for testosterone levels in the 
diagnosis of LOH might not exist. They propose there may be individual thresholds of 
testosterone levels according to the length of the AR CAG repeat polymorphism. This 
could have a pivotal role when deciding whether or not to start TRT in men with LOH 
(Zitzmann et al., 2007). 
 In the future, TRT could be modified by determining the AR CAG repeat 
polymorphism; men with shorter AR CAG repeats might require lower doses of TRT 
	  38	  	  
while men with longer repeats might need higher doses to reach normal levels (Zitzmann 
et al., 2007). 
 Zitzzman et al believe nonlinear calculation models could be used to assess the 
proper dose of TRT needed to reach the androgen effect while avoiding any adverse 
effects (Zitzmann et al., 2007). 
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RESULTS 
 The amount of research into the role testosterone plays in the physiology and 
pathology of older men has progressed rapidly over the last two decades. It has become 
evident that there is a decline in testosterone levels that are associated with older age. 
New research has shown testosterone to have a large impact on functions not related to 
the classical male hormone actions thought of in the past (Zitzmann, 2008). Low 
testosterone can cause anemia, osteoporosis, decrease of lean body mass, and an increase 
of body fat content (Zitzmann, 2008). There are also a number of psychological 
complaints of low testosterone such as fatigue, aggressiveness, decrease of cognitive 
abilities and depression (Zitzmann, 2008). Unfortunately, TRT does have side effects, the 
most common being excessive erythropoeisis and an increased Hct. 
 Testosterone’s stimulation of erythropoeisis is considered beneficial because a 
low RBC count is often found in men with low testosterone (Bhasin et al., 2010). In 
addition, anemia may contribute to complaints of weakness and fatigue, both of which 
are sings and symptoms suggestive of LOH. However, TRT may increase RBC 
production more than is desired and cause the blood to become too viscous (Bhasin et al., 
2010). Hct values greater than 52% are associated with increased blood viscosity, and 
there is evidence, from studies unrelated to TRT, that suggests elevated Hct can result in 
cerebral ischemia (Bhasin et al., 2010). However, it remains unclear whether high Hct 
caused by TRT has the same relevance on hemostasis. Although TRT has been shown to 
increase Hct, the incidence of cerebral vascular events hast not been affected as compared 
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to non-TRT treated men (Bhasin et al., 2010). It has also been shown that the effect of 
TRT on Hct is dose as well as age related (Zitzmann, 2007). 
 Zitzmann demonstrated that testosterone exerts its actions via ARs leading to 
gene transcription. The higher the number of CAG repeats, the lower the transcriptional 
activity of the AR (Zitzmann, 2008). It was also shown that short AR CAG repeats 
contribute to elevation of Hct during TRT. This mechanism impacts on both effects and 
side effects of TRT (Zitzmann, 2008). The AR CAG repeat polymorphism in the 
treatment of LOH with TRT seems to be of importance (Zitzmann, 2007). The normal 
length of AR CAG repeats is 9-37; longer lengths are associated with less physiological 
activity induced by TRT in vitro (Zitzmann, 2007). 
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DISCUSSION 
 In men, testosterone levels decrease in a slow progressive way as part of the 
normal aging process (Yassin, 2006). The age related decline of testosterone will rarely 
be manifest in men under the age of 50 years and becomes usually only quantitatively 
significant in men over 60 years of age (Yassin, 2006).  It is still controversial whether 
the age related decline of plasma testosterone levels constitutes a true clinical entity and 
whether this condition needs to be treated via TRT (Zitzmann, 2008). Professional 
organizations have formulated guidelines/recommendations for the administration of 
testosterone to elderly men (Bahsin, 2010). This demonstrates that there is a common 
agreement among experts in regard for the need to define LOH in various stages of the 
male life (Zitzmann, 2008). 
 A coworker of Dr. Steinach once noted that even if the restoration of libido was 
considered immoral or dangerous, the rejuvenation restores ones ability to work and 
improves the quality of life (Sengoopta, 2003. The “Ability to work” has been a key 
phrase in the history of TRT. The ‘inability to work’ is a common complaint of patients’. 
Patients’ electing to undergo treatment frequently report ‘enhanced energy and 
efficiency’ the earliest improvements after treatment (Sengoopta, 2003). 
 In 1960 a Swiss genitourinary surgeon, Paul Niehans, published the book 
Introduction to Cellular Therapy in which he envisions the replacement of organ 
transplantation by the injection of viable cells. For example, under functioning organs 
were treated with cells of the same organ, and cells of the antagonistic organ were 
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injected in cases of over function. Niehan believed this technique was a method for 
treating the whole organism on a biological basis, capable of revitalizing the human 
organism with trillions of cells by bringing to it those embryonic or young cells that it 
needs. Niehan contented that the injection of testicular cells increased the long-term 
excretion of testosterone derivatives. His patients included Pope Pius XII, Bernard 
Baruch and Aristotle Onassis. 
 Low testosterone is a common but not mandatory condition in elderly men. There 
are numerous indications that TRT has beneficial effects. Special care must be taken 
concerning erythropoeisis. Following the guidelines as specified by a number of 
professional organizations, truly testosterone deficient elderly men can be responsibly 
treated via TRT (Zitzmann, 2008). 
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